Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paracetamol in Neuropathic Pain
NCT03559985Phase 2
Key facts
- Status
- Terminated
- Start
- Aug 2018
- Primary completion
- Oct 2020
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- acetaminophen
- Conditions
- neuropathic pain
01
Overview
Phase 2, randomised, double-blind trial of acetaminophen in neuropathic pain (2 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Pain intensity change between period 1 and 2. Started Aug 2018; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Paracetamol then Placebo
Received Paracetamol in Period 1 and Placebo in Period 2
Placebo then Paracetamol
Received Placebo in Period 1 and Paracetamol in Period 2
03
Who it enrols
Adult patients (18-65) with chronic peripheral neuropathic pain (duration > 3 months) and pain intensity >= 3 on NPRS. Patients must not be taking daily paracetamol.
04
Endpoints
Primary
Pain intensity change between period 1 and 2
Secondary
Treatment responders at 30% (NPRS)
Treatment responders at 50% (NPRS)
Number of paroxysms
Paroxysms intensity (NPRS)
Assessment of paracetamol (and placebo) consumption
Assessment of dynamic mechanical allodynia
Assessment of liver and renal functions
Blood dosage of glutathione
Beyond the preview
Go deeper on NCT03559985.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03559985.